The Guardian | Oct 23 | A weak pound helped GSK post growth in revenues and earnings per share that exceeded expectations. But on constant exchange rate terms, the company saw a decline of 3% in sales overall and 13% in US sales as many of its products reached the "generic cliff.” click here